Chronic very low dose naltrexone administration attenuates opioid withdrawal expression

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• Opioid withdrawal management involves various agonist and antagonist drug regimens with inconsistent outcomes.
• Investigating the efficacy of low-dose opioid antagonists alongside agonists in mitigating withdrawal symptoms.

Purpose of the Study:

• To determine if extremely low quantities of opioid antagonists, when administered with opioid agonists, can reduce the expression of opioid withdrawal symptoms.
• To explore the neurobiological mechanisms underlying the potential reduction in withdrawal severity.

Main Methods:

• Morphine or placebo pellets were administered to male Sprague-Dawley rats for eight days.
• Rats received chronic low-dose naltrexone (5 mg/L) or unadulterated water, followed by acute naltrexone (100 mg/kg) or saline injection on day 8.
• Brain tissue (locus coeruleus and nucleus of the solitary tract) was analyzed for c-Fos, PKA, and pCREB expression using Western blot.

Main Results:

• Chronic administration of very low-dose naltrexone attenuated behavioral signs of opioid withdrawal.
• Reduced expression of c-Fos, protein kinase A (PKA), and phosphorylated cyclic adenosine monophosphate response element binding protein (pCREB) was observed in the NTS and LC.
• These molecular changes indicate decreased cellular activation in key brainstem areas.

Conclusions:

• Chronic, very low-dose naltrexone administration may reduce opioid withdrawal symptoms.
• This reduction may be attributed to decreased activation of brainstem noradrenergic neurons in morphine-dependent rats.
• Findings suggest a potential new therapeutic strategy for opioid withdrawal management.